[Oral anticoagulation in chronic kidney disease with atrial fibrillation]

Abstract

Atrial fibrillation is a common finding in patients with chronic kidney disease (CKD), which increases markedly the embolism risk. The CHADS2 and HAS-BLED scales, used in the general population to assess the risk/benefit of oral anticoagulation (OAC), underestimate respectively the risk of embolism and haemorrhage in CKD, making it difficult to decide whether to use OAC or not. Based on the available evidence, it seems indicated to use OAC in stage 3 CKD, while it is controversial in advanced stages. New OAC such as dabigatran and rivaroxaban have been approved in stage 3 CKD but their role is still somewhat uncertain.

Keywords: Anticoagulación oral; Atrial fibrillation; Chronic kidney disease; Enfermedad renal crónica; Fibrilación auricular; Haemodialysis; Hemodiálisis; Ictus; Oral anticoagulation; Stroke.